Delving into the Latest Updates on Alpha fetoprotein adenoviral vector vaccine(Jonsson Comprehensive Cancer Center) with Synapse

Overview

Basic Info

Drug Type

Vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication-

Inactive Indication

Hepatocellular Carcinoma

Originator Organization

Jonsson Comprehensive Cancer Center

Active Organization-

Inactive Organization

Jonsson Comprehensive Cancer Center

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of liver cancer.
PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage II, stage IIIA, stage IIIB, or stage IVA liver cancer.

Start Date-

Sponsor / Collaborator

Jonsson Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Alpha fetoprotein adenoviral vector vaccine(Jonsson Comprehensive Cancer Center)

Login to view more data

100 Translational Medicine associated with Alpha fetoprotein adenoviral vector vaccine(Jonsson Comprehensive Cancer Center)

Login to view more data

100 Patents (Medical) associated with Alpha fetoprotein adenoviral vector vaccine(Jonsson Comprehensive Cancer Center)

Login to view more data

100 Deals associated with Alpha fetoprotein adenoviral vector vaccine(Jonsson Comprehensive Cancer Center)

Login to view more data